Background: Atherosclerotic cardiovascular disease begins early in life and can be measured non-invasively at a pre-clinical stage using ultrasound-derived intima-media thickness (IMT) [1]. Early childhood efforts to prevent obesity may provide cardiovascular benefits, even without substantial changes in adiposity. The Communicating Healthy Beginnings Advice by Telephone (CHAT) trial was a nurse-led, telephone-based intervention conducted in Sydney, Australia, that aimed to support parental behaviours to reduce childhood obesity [2]. This study evaluated the effect of the CHAT intervention on vascular health in preschool-aged children.
Methods: Eligible children from the CHAT trial were invited for an in-person health assessment between the ages of 5 and 6 years. Abdominal aortic IMT (aIMT), the primary outcome, was measured using high-resolution ultrasound. evaluated whether the intervention affected aIMT directly or indirectly via BMI changes from infancy. To explore dose-response effects, participants were grouped by exposure across the trial’s two phases (birth–2 years and 2–4 years): no intervention, one phase, or both phases.
Results: The study included 92 mother-child dyads. At follow-up (mean age 5.8 ± 0.2 years), children had mean weight and height z-scores of 0.13 (±1.17) and 0.46 (±1.08), and a BMI z-score of -0.10 (±1.22), indicating a cohort taller and leaner than population norms. Males and females were evenly distributed. No significant difference in aIMT or BMI was observed between intervention and control groups. A dose-response trend suggested that children who received no intervention across both phases had higher aIMT compared to those with partial or full exposure (p = 0.04). However, the sample size was too small to draw firm conclusions.
Conclusions: Early-life obesity prevention trials may influence vascular health; however, they must be adequately powered. In addition, substantial resources are required to support in-person assessments and imaging. These considerations should be factored into the design and planning of future trials.